Secondary Logo

Institutional members access full text with Ovid®

Pneumocystis jirovecii Pneumonia in Patients With Autoimmune Disease on High-Dose Glucocorticoid

Chew, Li-Ching BMedSci, BMBS, MRCP, FAMS*†‡; Maceda-Galang, Liza Marie MD§; Tan, York Kiat MBBS, MRCP, FAMS*†‡; Chakraborty, Bibhas PhD; Thumboo, Julian MBBS, FRCP, FAMS*†‡

JCR: Journal of Clinical Rheumatology: March 2015 - Volume 21 - Issue 2 - p 72–75
doi: 10.1097/RHU.0000000000000215
Original Articles
Buy
SDC

Objective Indications for Pneumocystis jirovecii pneumonia (PCP) prophylaxis in patients with autoimmune disease remain unclear. We aimed to determine (1) the incidence of PCP in patients with autoimmune disease in general, in a clinical setting where prophylaxis is not routine, and (2) whether high-dose glucocorticoid (≥30 mg oral prednisolone or equivalent per day) is a risk factor for PCP infection.

Methods A retrospective review of the medical records of patients with autoimmune diseases hospitalized to a tertiary center over a 5-year study period was carried out. Patient demographics, mean glucocorticoid dose (in the last 1 month), and the outcomes of patients who developed PCP were analyzed.

Results The incidence rate of PCP infection was 75 per 100,000 patients per year. The in-hospital mortality was 50%, and all those who died were on high-dose glucocorticoid at the time of PCP diagnosis. There was a significant difference between the occurrence of PCP in patients who were on high-dose vs non–high-dose glucocorticoid (df = 1, P = 0.009), with a relative risk of 19 (P = 0.010; 95% confidence interval, 2.0–182.8). The mean oral prednisolone dose of patients who developed PCP and those who did not were 55.5 versus 10.7 mg, respectively, P = 0.002.

Conclusion High-dose glucocorticoid may be associated with an increased risk of PCP infection in patients with autoimmune diseases.

Supplemental digital content is available in the text.

From the *Department of Rheumatology and Immunology, Singapore General Hospital; †Duke-NUS Graduate Medical School; and ‡Yong Loo Lin School of Medicine, National University of Singapore, Singapore; §Section of Rheumatology, Makati Medical Center, Manila, Philippines; and ‖Centre for Quantitative Medicine, Duke-NUS Graduate Medical School, Singapore.

The authors declare no conflict of interest.

Correspondence: Li-Ching Chew, BMedSci, BMBS, MRCP, FAMS, Department of Rheumatology & Immunology, Level 4, Academia, 20 College Rd, Singapore 169856. E-mail: chew.li.ching@sgh.com.sg.

Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.nuclearmed.com).

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.